News

Samsung Biologics has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Under this agreement, Samsung…
Read More...

Moderna, Inc. and Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid…
Read More...

On Monday, September 14th, Eli Lilly and Company and Incyte announced initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of…
Read More...

Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, announced the completion of a $100 million Series…
Read More...

BioNTech SE announced the signing of a share purchase agreement with Novartis AG, Basel / Switzerland to acquire their GMP certified manufacturing facility in Marburg, Germany. The…
Read More...

Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi…
Read More...

Takeda Pharmaceutical Company Limited announced the expansion of its cell therapy manufacturing capabilities with the opening of a new 24,000 square-foot R&D cell therapy…
Read More...

Melior Pharmaceuticals (Melior) has been awarded a grant from the Commonwealth of Pennsylvania’s COVID-19 Vaccines, Treatments and Therapies (CV-VTT) Program, which is designed to…
Read More...

Junshi Biosciences a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that it has…
Read More...

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for magrolimab, a first-in-class, investigational anti-CD47…
Read More...

University of Pittsburgh School of Medicine scientists have isolated the smallest biological molecule to date that completely and specifically neutralizes the SARS-CoV-2 virus, which is…
Read More...

Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ and Lonza announced a strategic collaboration…
Read More...

CuraSen Therapeutics, Inc., a privately held clinical-stage biotechnology company, announced that it has dosed its first subjects in a multi-part, Phase 1 clinical study with CST-2032,…
Read More...

Novus Therapeutics, Inc. announced it has completed the acquisition of Anelixis Therapeutics, Inc. a privately held clinical stage biotechnology company developing a next generation…
Read More...

BioNTech SE announced that it will receive a grant of up to 375 million Euro from an initiative by the German Federal Ministry of Education and Research (BMBF) to support the…
Read More...

Axovant Gene Therapies Ltd announced that it has signed a strategic partnership with Viralgen, a leading Contract Development and Manufacturing Organization (CDMO). Leveraging the…
Read More...

Gilead Sciences, Inc. and Immunomedics announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in…
Read More...

HiFiBiO Therapeutics, a clinical-stage multinational biotherapeutics company focused on the development of novel antibodies in immunomodulation, announced a partnership agreement with…
Read More...

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patient has been dosed in a phase 2 study evaluating patritumab deruxtecan (U3-1402), a HER3…
Read More...

Seattle Genetics, Inc. and Merck, known as MSD outside the United States and Canada, announced two new strategic oncology collaborations. The companies will globally develop and…
Read More...